Posaconazole for the management of mucosal candidiasis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mucocutaneous candidiasis (MC) is one of the first signs of HIV infection. In the pre-highly active antiretroviral therapy (HAART) era, more than 90% of patients with HIV infection eventually developed some form of oral candidiasis during their illness, and an additional 10% developed esophageal candidiasis (EC). Although several antifungal agents are available, systemic azoles (e.g., fluconazole and itraconazole) have replaced older topical antifungals; (e.g., gentian violet and nystatin) in the management of MC in these patients. Overall, the azoles are safe and effective agents in HIV-infected patients with MC. However, clinical relapses are extremely common in HIV patients not on HAART or who are noncompliant. The relapses are dependent on the degree of immunosuppression and are more common following treatment with clotrimazole or ketoconazole than with fluconazole or itraconazole. Posaconazole is a new extended-spectrum triazole recently approved for the management of oropharyngeal candidiasis (OPC). In vitro, posaconazole possesses potent activity against Candida species, including strains that are resistant to fluconazole. Recent clinical trials demonstrate that posaconazole is as efficacious as fluconazole in producing a successful clinical response in HIV-infected patients with OPC/EC. In addition, posaconazole has been demonstrated to be well tolerated and more effective in sustaining clinical success after treatment was discontinued. Posaconazole appears to be an effective alternative in the management of MC in these difficult-to-treat infections.

Original languageEnglish (US)
Pages (from-to)245-256
Number of pages12
JournalFuture Microbiology
Volume2
Issue number3
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Candidiasis
Fluconazole
Azoles
Itraconazole
Highly Active Antiretroviral Therapy
HIV
HIV Infections
Clotrimazole
Gentian Violet
Oral Candidiasis
Nystatin
Recurrence
Triazoles
Ketoconazole
posaconazole
Antifungal Agents
Candida
Immunosuppression
Clinical Trials
Therapeutics

Keywords

  • Esophageal candidiasis
  • HIV infection
  • Oropharyngeal candidiasis
  • Posaconazole

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Posaconazole for the management of mucosal candidiasis. / Vazquez, Jose A.

In: Future Microbiology, Vol. 2, No. 3, 01.06.2007, p. 245-256.

Research output: Contribution to journalArticle

@article{63f9b744e77b45129a0dd8857d6ff29a,
title = "Posaconazole for the management of mucosal candidiasis",
abstract = "Mucocutaneous candidiasis (MC) is one of the first signs of HIV infection. In the pre-highly active antiretroviral therapy (HAART) era, more than 90{\%} of patients with HIV infection eventually developed some form of oral candidiasis during their illness, and an additional 10{\%} developed esophageal candidiasis (EC). Although several antifungal agents are available, systemic azoles (e.g., fluconazole and itraconazole) have replaced older topical antifungals; (e.g., gentian violet and nystatin) in the management of MC in these patients. Overall, the azoles are safe and effective agents in HIV-infected patients with MC. However, clinical relapses are extremely common in HIV patients not on HAART or who are noncompliant. The relapses are dependent on the degree of immunosuppression and are more common following treatment with clotrimazole or ketoconazole than with fluconazole or itraconazole. Posaconazole is a new extended-spectrum triazole recently approved for the management of oropharyngeal candidiasis (OPC). In vitro, posaconazole possesses potent activity against Candida species, including strains that are resistant to fluconazole. Recent clinical trials demonstrate that posaconazole is as efficacious as fluconazole in producing a successful clinical response in HIV-infected patients with OPC/EC. In addition, posaconazole has been demonstrated to be well tolerated and more effective in sustaining clinical success after treatment was discontinued. Posaconazole appears to be an effective alternative in the management of MC in these difficult-to-treat infections.",
keywords = "Esophageal candidiasis, HIV infection, Oropharyngeal candidiasis, Posaconazole",
author = "Vazquez, {Jose A.}",
year = "2007",
month = "6",
day = "1",
doi = "10.2217/17460913.2.3.245",
language = "English (US)",
volume = "2",
pages = "245--256",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Posaconazole for the management of mucosal candidiasis

AU - Vazquez, Jose A.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Mucocutaneous candidiasis (MC) is one of the first signs of HIV infection. In the pre-highly active antiretroviral therapy (HAART) era, more than 90% of patients with HIV infection eventually developed some form of oral candidiasis during their illness, and an additional 10% developed esophageal candidiasis (EC). Although several antifungal agents are available, systemic azoles (e.g., fluconazole and itraconazole) have replaced older topical antifungals; (e.g., gentian violet and nystatin) in the management of MC in these patients. Overall, the azoles are safe and effective agents in HIV-infected patients with MC. However, clinical relapses are extremely common in HIV patients not on HAART or who are noncompliant. The relapses are dependent on the degree of immunosuppression and are more common following treatment with clotrimazole or ketoconazole than with fluconazole or itraconazole. Posaconazole is a new extended-spectrum triazole recently approved for the management of oropharyngeal candidiasis (OPC). In vitro, posaconazole possesses potent activity against Candida species, including strains that are resistant to fluconazole. Recent clinical trials demonstrate that posaconazole is as efficacious as fluconazole in producing a successful clinical response in HIV-infected patients with OPC/EC. In addition, posaconazole has been demonstrated to be well tolerated and more effective in sustaining clinical success after treatment was discontinued. Posaconazole appears to be an effective alternative in the management of MC in these difficult-to-treat infections.

AB - Mucocutaneous candidiasis (MC) is one of the first signs of HIV infection. In the pre-highly active antiretroviral therapy (HAART) era, more than 90% of patients with HIV infection eventually developed some form of oral candidiasis during their illness, and an additional 10% developed esophageal candidiasis (EC). Although several antifungal agents are available, systemic azoles (e.g., fluconazole and itraconazole) have replaced older topical antifungals; (e.g., gentian violet and nystatin) in the management of MC in these patients. Overall, the azoles are safe and effective agents in HIV-infected patients with MC. However, clinical relapses are extremely common in HIV patients not on HAART or who are noncompliant. The relapses are dependent on the degree of immunosuppression and are more common following treatment with clotrimazole or ketoconazole than with fluconazole or itraconazole. Posaconazole is a new extended-spectrum triazole recently approved for the management of oropharyngeal candidiasis (OPC). In vitro, posaconazole possesses potent activity against Candida species, including strains that are resistant to fluconazole. Recent clinical trials demonstrate that posaconazole is as efficacious as fluconazole in producing a successful clinical response in HIV-infected patients with OPC/EC. In addition, posaconazole has been demonstrated to be well tolerated and more effective in sustaining clinical success after treatment was discontinued. Posaconazole appears to be an effective alternative in the management of MC in these difficult-to-treat infections.

KW - Esophageal candidiasis

KW - HIV infection

KW - Oropharyngeal candidiasis

KW - Posaconazole

UR - http://www.scopus.com/inward/record.url?scp=34547573733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547573733&partnerID=8YFLogxK

U2 - 10.2217/17460913.2.3.245

DO - 10.2217/17460913.2.3.245

M3 - Article

C2 - 17661697

AN - SCOPUS:34547573733

VL - 2

SP - 245

EP - 256

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 3

ER -